Keros Therapeutics Inc (KROS)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Keros Therapeutics Inc chart...

About the Company

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i

Exchange

NASDAQ

Website

kerostx.com

$55M

Total Revenue

104

Employees

$2B

Market Capitalization

-13.31

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $KROS News

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

4d ago, source:

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...

KROS Keros Therapeutics, Inc.

5d ago, source: Seeking Alpha

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...

Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable

19d ago, source: Hosted on MSN

Keros Therapeutics, Inc. (KROS) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. A solid price ...

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

13d ago, source: Business Insider

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

19d ago, source: Business Insider

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical ...

Keros Therapeutics Inc KROS

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

19d ago, source: Finanznachrichten

KEROS THERAPEUTICS, INC. Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) DECEMBER 31, 2023 2022 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 331,147 ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...